Natera: $8.25M Prenatal Test Class Action Settlement Approved

• Natera has settled a class action lawsuit for $8.25 million regarding its Panorama and Vasistera prenatal tests.
• The lawsuit alleged Natera misleadingly marketed its tests as highly accurate despite known high false positive rates for rare genetic conditions.
• U.S. District Judge Jon Tigar approved the settlement, which allocates funds for class member payouts, attorney fees, and class representative awards.
• As part of the agreement, Natera will update its website to clarify that its prenatal tests are screening tools, not diagnostic, and require confirmation for high-risk results.
• The settlement followed a 2022 New York Times report and highlighted concerns about how false positive NIPT results could influence pregnancy decisions.

This resolution underscores the significant litigation risks faced by healthcare and biotechnology companies whose marketing of sensitive health-related products might be interpreted as misrepresenting accuracy or capabilities.

Genetic testing company Natera has agreed to an $8.25 million settlement in a class action lawsuit concerning its noninvasive prenatal tests, Panorama and Vasistera. U.S. District Judge Jon Tigar formally approved the final settlement, which addresses claims that the company's marketing overstated the accuracy of these tests, potentially influencing critical pregnancy decisions for expectant parents.

The settlement class encompasses all individuals in the United States who purchased at least one Natera noninvasive prenatal test under the Panorama or Vasistera names during the specified class period. This resolution brings to a close a significant legal challenge for the company, focusing on consumer protection issues related to its widely used genetic screening products.

This Natera prenatal test class action settlement underscores the growing scrutiny over the marketing practices of companies in the genetic testing industry, particularly regarding the clarity and accuracy of information provided to consumers about sensitive health screenings.

The lawsuit, which contributed to the broader landscape of genetic testing false positive litigation, alleged that Natera promoted its prenatal tests as highly accurate. However, plaintiffs contended that the company was aware these tests could produce a high percentage of false positives for rare genetic conditions, potentially leading to undue anxiety or difficult decisions for pregnant individuals.

These noninvasive prenatal tests (NIPTs) require only a blood sample, offering a less intrusive option compared to more accurate, but invasive, diagnostic procedures like amniocentesis, which involves extracting amniotic fluid and cells and carries risks such as miscarriage and infection. The core of the Natera false positive NIPT lawsuit revolved around the assertion that the company marketed these screening tools as reliable indicators of fetal abnormalities without adequately disclosing the chance of false positives.

The legal action followed a 2022 New York Times report that highlighted how prenatal tests designed to screen for genetic disorders, including Down syndrome, early in pregnancy could yield a significant number of false positive results for extremely rare conditions. Plaintiffs specifically accused Natera of violating consumer protection laws in multiple states, including California, Florida, Illinois, Maryland, and New Jersey, through its marketing practices.

U.S. District Judge Jon Tigar, a Barack Obama appointee, issued an 18-page order affirming the settlement as fair, reasonable, and adequate, noting it met the common prerequisites for approval. The agreement was reached through arm's-length negotiations with a mediator, a factor Judge Tigar cited in his decision. He emphasized that the settlement offers substantial recoveries for class members, particularly when weighed against the inherent risks and costs associated with protracted litigation, including the potential for appeals.

From the $8.25 million settlement fund, Judge Tigar awarded approximately $2.4 million, or 30%, for attorney fees, alongside over $200,000 to cover out-of-pocket expenses. Additionally, each of the eight class representatives received an award of $7,500. Class members who submit a claim with proof of purchase for a Natera test can receive up to 10% of their expenses if their costs exceeded $300, while claimants without proof of purchase are eligible for up to $30.

Following preliminary approval of the settlement in December 2025, the settlement administrator, Simpluris, Inc., encountered difficulties notifying some potential class members via emails and postcards. After an investigation in March to resolve these issues, Judge Tigar extended the deadline for class members to submit claims or opt-out to July, ensuring that over 98% of the settlement class received notice. The class period for eligibility varies by state, commencing on February 17, 2016, for Ohio, and by February 17, 2018, for all other states.

While Natera did not admit liability as part of the settlement, the company committed to implementing changes in its website language. This includes adding clear explanations that its prenatal tests are screening tests, not diagnostic tools, and that any high-risk results should be confirmed through actual diagnostic testing. This modification directly addresses a central concern of the Natera consumer protection lawsuit, emphasizing the distinction between screening and diagnosis.

This resolution underscores the significant litigation risks faced by healthcare and biotechnology companies whose marketing of sensitive health-related products might be interpreted as misrepresenting accuracy or capabilities. The agreement highlights the importance of transparent communication regarding the limitations and intended use of medical tests, particularly those that can profoundly impact personal health decisions.

The outcome of this Natera class action serves as a crucial reminder for the genetic testing industry to ensure that all public-facing information, especially concerning test accuracy and purpose, is unequivocally clear and robustly disclaimed to mitigate future consumer protection and class action exposure.

This settlement highlights the significant litigation risk for healthcare and biotech companies whose product marketing, particularly for sensitive health-related tests, could be construed as misrepresenting accuracy or capabilities. Compliance officers should review all marketing and website language to ensure clear distinctions between screening and diagnostic tests, and to include robust disclaimers to mitigate consumer protection and class action exposure.

Source: Original reporting via Courthouse News